Amniocenthesis: safe invazive method in prenatal diagnostics
Authors:
MUDr. Karel Čutka; MUDr. David Čutka; MUDr. Milada Šustrová
Authors‘ workplace:
Centrum lékařské genetiky, České Budějovice
Published in:
Prakt Gyn 2007; 11(1): 23-25
Overview
The article shows an overview of development of amniocenthesis rate (AC) as a basic invazive method in prenatal diagnostics. Czech Rep. in y. 2005 16,5% AC, while 17% of pregnant women underwent some invazive method of prenatal diagnostics. Detection of Down syndrome in Czech Rep. in y. 2005 was 76%, (70% in 1999-2005). Center of Human Genetics (CLG) y. 2005 19% AC while 100% of Down sy was detected (in years 1999-2005 detection 91%). Comparison of abortion rate in female population with AC and overall abortion occurence (AB) in female population in 2nd trimester. The risks do not vary – the AB risk in a group of patients with AC in Center of Human Genetics is not enhanced. The abortion of fetuses is usually caused by dysfunction of placenta, thrombophile mutations or navelwort complication (therefore no relation to performance of AC) To a significant reduction of the number of amniocentheses in population may lead the serum integrated test which is recommended as the best test in areas where measurement of NT by accredited sonographer is not available. Integrated test (completion of measurement of NT by accredited sonographer to biochemical markers of the first and second trimester) is the best screening test with highest detection rate and the lowest false pozitive rate, however, it is accessible to a small part of the population.
Key words:
amniocenthesis - spontaneous abortion- no enhanced risk – detection of Down syndrom – serum integrated test – integrated test
Sources
1. Pettker C, Copel J. Amniocentéza: technika a komplikace. Gynekologie po promoci 2006; 6(1): 32.
2. Gregor V, Šípek A. Prenatální diagnostika v roce 2005. Kaprasův den – Klinická genetika. 2006.
3. Tabor A, Philip J, Madsen M et al. Randomised controlled trial of genetic amniocetesis in 4606 low-risk women. Lancet 1986; 1: 1287-1293.
4. Calda P, Víšková H. Příliš mnoho možností jak screenovat populaci na výskyt Downova syndromu – aneb jak invazivní diagnostika ovlivňuje výsledky prenatální péče. Mod Gynek Porod 2004; 13(1): 119-120.
5. Eddleman K, Berkowitz R, Kharbutli Y et al. Pregnancy loss rates after midtrimester amniocentesis: The FASTER Trial. Am J Obstet Gynecol 2003; 189: S111.
6. Tongsong T, Wanapirak C, Sirivatanapa P et al. Amniocentesis – related fetal loss: a cohort study. Obstet Gynecol 1998; 99: 64-67.
7. ÚZIS ČR, zdravotní statistika. Potraty 2003 2004; 43: 105.
8. ÚZIS ČR, zdravotní statistika. Narození 2003 2004; 43: 16.
9. Vlk R. Amniocentéza. Gynek po Prom 2006; 6(1): 40-42.
10. Wald NJ, Rodeck C, Hackshaw AK et al. First and second trimester antenatal screening for Down´s syndrome: the results of Serum, Urine and Ultrasound Screening Study (SURRUS). Health Technol Assess 2003; 7: 24-27.
11. Malone F, Canick JA, Ball RH et al. First-trimester or second-trimester screening, or both, for Down´s syndrome. First and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. N Engl J Med 2005; 353: 2001-2011.
12. ACOG Practice Bulletin No.77. Screening for Fetal Chromosomal Abnormalities. Obstet Gynecol 2007; 109: 217-227.
13. Model of best practice for providing Down's Syndrome screening services. Department of Health. www.dh.gov.uk.
14. Antenatal Screening for Down Syndrome. Royal College of Obstetricians and Gynaecologists. www.rcog.org.uk/resources/public/pdf/down_syndrome_screening.pdf.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Practical Gynecology
2007 Issue 1
Most read in this issue
- Optimal management in patients undergoing caesarean section in spinal anaesthesia
- Bronchial Asthma in Pregnancy
- Rooming in
- Amniocenthesis: safe invazive method in prenatal diagnostics